ULTRACAINE D-S FORTE INJECTION SOLUTION

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

EPINEPHRINE; ARTICAINE HYDROCHLORIDE

Disponible desde:

HANSAMED LIMITED

Código ATC:

N01BB58

Designación común internacional (DCI):

ARTICAINE, COMBINATIONS

Dosis:

0.01MG; 40MG

formulario farmacéutico:

SOLUTION

Composición:

EPINEPHRINE 0.01MG; ARTICAINE HYDROCHLORIDE 40MG

Vía de administración:

BLOCK/INFILTRATION

Unidades en paquete:

1.7 ML

tipo de receta:

Ethical

Área terapéutica:

LOCAL ANESTHETICS

Resumen del producto:

Active ingredient group (AIG) number: 0226661001; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2000-08-02

Ficha técnica

PRODUCT MONOGRAPH
ULTRACAINE D-S INJECTION _ _
(4% articaine hydrochloride with epinephrine 1:200,000 as epinephrine
hydrochloride)
ULTRACAINE D-S FORTE INJECTION_ _
(4% articaine hydrochloride with epinephrine 1:100,000 as epinephrine
hydrochloride)
Solutions for Injection_ _
Local Anesthetic for Dental Use
Date of Preparation
July 19, 2000
Manufactured by:
Sanofi - Aventis Deutschland GmbH
DATE OF REVISION:
Frankfurt am Main, Hessen, Germany
JANUARY 27, 2014
Imported by:
HANSAmed Limited
2830 Argentia Road, Unit 5 - 8
Mississauga, Ontario L5N 8G4
Submission Control No. 162166
“
ULTRACAINE
” is the registered trademark of Sanofi-Aventis Deutschland GmbH.
_Ultracaine D-S, Ultracaine D-S Forte (articaine + epinephrine
solution for injection) _
_Hansamed Ltd _
_Page 2 of 20 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................
3
SUMMARY PRODUCT INFORMATION
...........................................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................................
3
CONTRAINDICATIONS
....................................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................................
4
ADVERSE REACTIONS
....................................................................................................................
6
DRUG INTERACTIONS
....................................................................................................................
7
DOSAGE AND ADMINISTRATION
...................................................................................................
7
OVERDOSAGE
.................................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
..........................